[Effect of an inhaled beta-2-adrenergic agent administered at the time of delayed bronchial reactions to occupational agents].
We previously showed in a retrospective study that the acute response to an inhaled beta-2-adrenergic agent is marked in late asthmatic reactions (J Allergy Clin Immunology 1990;85:834). In a double-blind prospective study, we assessed the magnitude and duration of the effect of inhaled salbutamol (200 micrograms) compared to a placebo in 22 subjects who experienced late asthmatic reactions (sustained fall in FEV 1 > or = 20%) after specific inhalation challenges in the laboratory with various occupational agents (isocyanates in 9 subjects). Before salbutamol was administered, the % in FEV1 over the pre-challenge values did not differ between the placebo (31 +/- 8%, n = 12) and the active (28 +/- 6%, n = 10) groups. The % recovery in FEV1 over the pre-bronchodilator value was 9 +/- 11% in the placebo group and 28 +/- 11% in the active group (t = 4.0, p < 0.001). The % recovery in FEV1 assessed in comparison with pre-challenge values was up to 80 +/- 17% in the placebo group and up to 95 +/- 6% in the active group (t = 2.85, p < 0.01). The 10 subjects on active medication had FEV1 values > or = 80% of the pre-challenge value one hour after inhaling salbutamol. The pattern of diminution in the bronchodilator effect was similar in the eight subjects with occupational asthma on active medication who remained for more than one hour as compared to a control group of asthmatic subjects paired for the degree of baseline airway obstruction. These data show that late asthmatic reactions are satisfactorily reversed with inhaled bronchodilator and that the duration of the effect is as satisfactory for subjects with occupational asthma as it is for asthmatic subjects.
Malo
J L
JL
Service de Pneumologie, Hôpital du Sacré-Coeur, Gouin, Montréal, Canada.
Perrin
B
B
L'Archevêque
J
J
Ghezzo
H
H
Cartier
A
A
D000280:Administration, Inhalation; D000328:Adult; D000420:Albuterol / Q000494:pharmacology / Q000627:therapeutic use*; D001249:Asthma / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D001985:Bronchial Provocation Tests; D004311:Double-Blind Method; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D009784:Occupational Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos; D011446:Prospective Studies; D013997:Time Factors
D010919:Placebos; D000420:Albuterol
Effet d'un agent bêta-2-adrénergique inhalé administré au moment des réactions bronchiques retardées après exposition à des agents professionnels.